Brain distribution of a novel MEK Inhibitor E6201: Implications in the treatment of melanoma brain metastases

Medicine & Life Sciences

• Mitogen-Activated Protein Kinase Kinases 67%
• Melanoma 51%
• Neoplasm Metastasis 38%
• Brain 30%
• ATP Binding Cassette Transporter, Subfamily B, Member 1 12%
• Brain Neoplasms 10%
• MAP Kinase Kinase Kinases 7%
• Breast Neoplasms 7%
• Central Nervous System Neoplasms 6%
• Madin Darby Canine Kidney Cells 6%
• Active Biological Transport 6%
• Proteins 6%
• Mitogens 5%
• Mitogen-Activated Protein Kinases 5%
• Glioblastoma 5%
• Blood-Brain Barrier 5%
• Knockout Mice 5%
• Inhibitory Concentration 50 5%
• In Vitro Techniques 4%
• Pharmaceutical Preparations 4%
• Area Under Curve 4%
• Central Nervous System 4%

Chemical Compounds

• EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinase) Inhibitor 100%
• Protein 25%
• IC50 21%
• Resistance 19%
• Plasma 19%
• Dose 11%
• Drug 8%